Surface PEGylation suppresses pulmonary effects of CuO in allergen-induced lung inflammation.
Animals
Copper
/ chemistry
Female
Gene Expression Profiling
Genome-Wide Association Study
Mice, Inbred BALB C
Nanoparticles
/ chemistry
Neutrophil Infiltration
/ drug effects
Ovalbumin
/ immunology
Pneumonia
/ chemically induced
Polyethylene Glycols
/ chemistry
Surface Properties
Transcriptome
/ drug effects
Allergic airway inflammation
Asthma
CuO
Engineered nanomaterial
Health effects
Inflammation
Risk assessment
Journal
Particle and fibre toxicology
ISSN: 1743-8977
Titre abrégé: Part Fibre Toxicol
Pays: England
ID NLM: 101236354
Informations de publication
Date de publication:
05 07 2019
05 07 2019
Historique:
received:
20
07
2018
accepted:
04
06
2019
entrez:
7
7
2019
pubmed:
7
7
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Copper oxide (CuO) nanomaterials are used in a wide range of industrial and commercial applications. These materials can be hazardous, especially if they are inhaled. As a result, the pulmonary effects of CuO nanomaterials have been studied in healthy subjects but limited knowledge exists today about their effects on lungs with allergic airway inflammation (AAI). The objective of this study was to investigate how pristine CuO modulates allergic lung inflammation and whether surface modifications can influence its reactivity. CuO and its carboxylated (CuO COOH), methylaminated (CuO NH Our data demonstrates that although CuO materials did not considerably influence hallmarks of allergic airway inflammation, the materials exacerbated the existing lung inflammation by eliciting dramatic pulmonary neutrophilia. Transcriptomic analysis showed that CuO, CuO COOH and CuO NH CuO as well as its functionalized forms worsen allergic airway inflammation by causing neutrophilia in the lungs, however, our results also show that surface PEGylation can be a promising approach for inhibiting the effects of pristine CuO. Our study provides information for health and safety assessment of modified CuO materials, and it can be useful in the development of nanomedical applications.
Sections du résumé
BACKGROUND
Copper oxide (CuO) nanomaterials are used in a wide range of industrial and commercial applications. These materials can be hazardous, especially if they are inhaled. As a result, the pulmonary effects of CuO nanomaterials have been studied in healthy subjects but limited knowledge exists today about their effects on lungs with allergic airway inflammation (AAI). The objective of this study was to investigate how pristine CuO modulates allergic lung inflammation and whether surface modifications can influence its reactivity. CuO and its carboxylated (CuO COOH), methylaminated (CuO NH
RESULTS
Our data demonstrates that although CuO materials did not considerably influence hallmarks of allergic airway inflammation, the materials exacerbated the existing lung inflammation by eliciting dramatic pulmonary neutrophilia. Transcriptomic analysis showed that CuO, CuO COOH and CuO NH
CONCLUSIONS
CuO as well as its functionalized forms worsen allergic airway inflammation by causing neutrophilia in the lungs, however, our results also show that surface PEGylation can be a promising approach for inhibiting the effects of pristine CuO. Our study provides information for health and safety assessment of modified CuO materials, and it can be useful in the development of nanomedical applications.
Identifiants
pubmed: 31277695
doi: 10.1186/s12989-019-0309-1
pii: 10.1186/s12989-019-0309-1
pmc: PMC6612204
doi:
Substances chimiques
Polyethylene Glycols
3WJQ0SDW1A
Copper
789U1901C5
Ovalbumin
9006-59-1
cupric oxide
V1XJQ704R4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Références
Int J Nanomedicine. 2016 Aug 11;11:3859-74
pubmed: 27570453
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Annu Rev Physiol. 2010;72:495-516
pubmed: 20148686
Part Fibre Toxicol. 2017 Aug 1;14(1):28
pubmed: 28764715
Sci Rep. 2015 Oct 28;5:15824
pubmed: 26508362
Adv Mater. 2010 Jun 25;22(24):2601-27
pubmed: 20512811
Part Fibre Toxicol. 2017 Nov 21;14(1):45
pubmed: 29157272
Nano Lett. 2010 Sep 8;10(9):3656-64
pubmed: 20695477
PLoS One. 2013 Aug 05;8(8):e69534
pubmed: 23940521
Nat Rev Immunol. 2008 Mar;8(3):183-92
pubmed: 18274560
Toxicol Lett. 2010 Sep 1;197(3):169-74
pubmed: 20621582
Arch Toxicol. 2014 Feb;88(2):489-99
pubmed: 23948970
Free Radic Biol Med. 2010 Apr 1;48(7):924-34
pubmed: 20093178
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Part Fibre Toxicol. 2010 Nov 25;7:35
pubmed: 21108815
Pharmaceuticals (Basel). 2016 Nov 30;9(4):
pubmed: 27916867
Allergy Asthma Clin Immunol. 2006 Sep 15;2(3):98-108
pubmed: 20525154
Nucleic Acids Res. 2017 Jan 4;45(D1):D183-D189
pubmed: 27899595
Immunol Rev. 2017 Jul;278(1):131-144
pubmed: 28658557
Nanomedicine (Lond). 2015;10(15):2365-77
pubmed: 26251192
Part Fibre Toxicol. 2013 Jul 01;10:26
pubmed: 23815813
Environ Sci Technol. 2007 Jun 1;41(11):4158-63
pubmed: 17612205
Chem Res Toxicol. 2012 Jul 16;25(7):1512-21
pubmed: 22686560
Ecotoxicol Environ Saf. 2018 Oct 30;162:633-646
pubmed: 30033160
J Clin Invest. 2010 Jul;120(7):2423-31
pubmed: 20516641
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
J Appl Toxicol. 2018 Mar;38(3):385-397
pubmed: 29094763
ACS Nano. 2011 Dec 27;5(12):9326-38
pubmed: 22077320
Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1787-93
pubmed: 19608967
Biol Pharm Bull. 2012;35(12):2133-40
pubmed: 23207765
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Nat Immunol. 2010 Jul;11(7):577-84
pubmed: 20562844
J Appl Toxicol. 2017 Jan;37(1):84-91
pubmed: 27687502
Nat Immunol. 2015 Jan;16(1):45-56
pubmed: 25521684
J Biomed Mater Res A. 2003 Jul 1;66(1):62-78
pubmed: 12833432
Nanotoxicology. 2016;10(4):445-52
pubmed: 26472121
Am J Respir Crit Care Med. 2001 Feb;163(2):517-23
pubmed: 11179133
ACS Appl Mater Interfaces. 2016 Nov 23;8(46):31806-31812
pubmed: 27791350
J Proteome Res. 2017 Feb 3;16(2):689-697
pubmed: 27973853
Toxicol Ind Health. 2016 May;32(5):809-21
pubmed: 24311626
Chem Res Toxicol. 2008 Sep;21(9):1726-32
pubmed: 18710264
Part Fibre Toxicol. 2018 May 3;15(1):20
pubmed: 29724254
Inhal Toxicol. 2013 Mar;25(4):179-91
pubmed: 23480194
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Science. 1994 Mar 18;263(5153):1600-3
pubmed: 8128245
Annu Rev Pharmacol Toxicol. 2016;56:41-57
pubmed: 26514197
Toxicol Lett. 2009 Jul 24;188(2):112-8
pubmed: 19446243
PLoS One. 2011 Feb 17;6(2):e17236
pubmed: 21359146
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Exp Mol Med. 2015 Jul 17;47:e173
pubmed: 26183169
Phys Med Biol. 2015 Aug 7;60(15):5767-83
pubmed: 26159685
Nanoscale. 2016 Oct 06;8(39):17322-17332
pubmed: 27714104
Ecotoxicol Environ Saf. 2018 Dec 30;166:462-473
pubmed: 30296611
Am J Dermatopathol. 2005 Jun;27(3):277-8
pubmed: 15900138
Nat Rev Immunol. 2001 Nov;1(2):108-16
pubmed: 11905818
Nanotoxicology. 2016 Oct;10(8):1084-95
pubmed: 27132941
Toxicol Appl Pharmacol. 2009 Jun 15;237(3):306-16
pubmed: 19371758
J Photochem Photobiol B. 2017 Jun;171:133-138
pubmed: 28501691
Curr Opin Immunol. 2013 Dec;25(6):755-60
pubmed: 24035139